Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082522 | 0.92 | TP53 (0.82) | TP53LMNAFGFR1TDP1RXFP1 | |
| SCHEMBL16082486 | 0.90 | TP53 (0.77) | TP53LMNAFGFR1TDP1RXFP1 | |
| SCHEMBL16082518 | 0.90 | TP53 (1.00) | TP53LMNATDP1SMN1; SMN2MAPT | |
| SCHEMBL16082498 | 0.90 | TP53 (0.85) | TP53LMNATDP1RXFP1CASP6 | |
| SCHEMBL16082482 | 0.88 | TP53 (0.80) | TP53LMNAFGFR1TDP1RXFP1 | |
| SCHEMBL16082478 | 0.88 | TP53 (0.80) | TP53LMNAFGFR1SMN1; SMN2MAPT | |
| SCHEMBL16082912 | 0.86 | TP53 (0.76) | TP53LMNAFGFR1TDP1RXFP1 | |
| SCHEMBL16082484 | 0.85 | TP53 (0.84) | TP53LMNATDP1RXFP1CASP6 | |
| SCHEMBL16082520 | 0.85 | TP53 (0.76) | TP53LMNATDP1RXFP1CASP6 | |
| SCHEMBL16082499 | 0.85 | TP53 (0.70) | TP53LMNATDP1RXFP1CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790188-B2 | Benzimidazole derivatives and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160031824-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014145887-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031824-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | TARDBP, ADRM1, MDM2 | TP53 50/4885LMNA 2199/4885FGFR1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.